<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bristol-myers Squibb Company — News on 6ix</title>
<link>https://6ix.com/company/bristol-myers-squibb-company</link>
<description>Latest news and press releases for Bristol-myers Squibb Company on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 10:59:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bristol-myers-squibb-company" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354e8678dffbe2df0e665c.webp</url>
<title>Bristol-myers Squibb Company</title>
<link>https://6ix.com/company/bristol-myers-squibb-company</link>
</image>
<item>
<title>Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-and-pfizer-to-make-eliquisr-apixaban-available-via-mark-cuban-cost-plus-drug-company</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-and-pfizer-to-make-eliquisr-apixaban-available-via-mark-cuban-cost-plus-drug-company</guid>
<pubDate>Fri, 24 Apr 2026 10:59:00 GMT</pubDate>
<description>PRINCETON, N.J., April 24, 2026--Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company</description>
</item>
<item>
<title>Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/atrium-therapeutics-earns-dollar15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/atrium-therapeutics-earns-dollar15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration</guid>
<pubDate>Thu, 23 Apr 2026 12:00:00 GMT</pubDate>
<description>Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE: BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration.</description>
</item>
<item>
<title>Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/foundation-medicine-expands-existing-collaboration-with-bristol-myers-squibb-to-develop-a-next-generation-sequencing-companion-diagnostic-to-identify-patients-with-homozygous-mtap-deletion</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/foundation-medicine-expands-existing-collaboration-with-bristol-myers-squibb-to-develop-a-next-generation-sequencing-companion-diagnostic-to-identify-patients-with-homozygous-mtap-deletion</guid>
<pubDate>Tue, 21 Apr 2026 11:00:00 GMT</pubDate>
<description>BOSTON, April 21, 2026--Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine’s longstanding relationship in advancing biomarker-driven therapies with Bris</description>
</item>
<item>
<title>Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/oxford-biotherapeutics-enters-strategic-collaboration-with-bristol-myers-squibb-to-discover-and-develop-next-generation-t-cell-engagers-for-solid-tumours</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/oxford-biotherapeutics-enters-strategic-collaboration-with-bristol-myers-squibb-to-discover-and-develop-next-generation-t-cell-engagers-for-solid-tumours</guid>
<pubDate>Thu, 09 Apr 2026 11:00:00 GMT</pubDate>
<description>Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s third major pharma collaboration within the past 12 months and reflects strong validation of the OGAP®-Verify platform's potential to drive oncology innovationOBT to receive an upfront payment and may be eligible to receive milestone payments, as well as royalties on net sales Oxford, UK and San Jose</description>
</item>
<item>
<title>Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-evolves-and-expands-standing-in-the-gaap-to-advance-more-equitable-care-in-multiple-myeloma-as-program-marks-ten-years</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-evolves-and-expands-standing-in-the-gaap-to-advance-more-equitable-care-in-multiple-myeloma-as-program-marks-ten-years</guid>
<pubDate>Wed, 01 Apr 2026 11:29:00 GMT</pubDate>
<description>New survey, guided by patient advocacy input, seeks to elevate lived experience and community voice to better understand challenges in multiple myeloma care PRINCETON, NJ / ACCESS Newswire / April 1, 2026 /Originally published by Bristol Myers Squibb ...</description>
</item>
<item>
<title>Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-presents-positive-results-from-phase-3-scout-hcm-trial-demonstrating-efficacy-and-safety-of-camzyos-mavacamten-in-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-presents-positive-results-from-phase-3-scout-hcm-trial-demonstrating-efficacy-and-safety-of-camzyos-mavacamten-in-adolescents-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-ohcm</guid>
<pubDate>Sun, 29 Mar 2026 15:45:00 GMT</pubDate>
<description>PRINCETON, N.J., March 29, 2026--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM</description>
</item>
<item>
<title>Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/open-label-outpatient-switch-study-demonstrates-symptom-stability-during-transition-from-oral-atypical-antipsychotics-to-cobenfytm-xanomeline-and-trospium-chloride</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/open-label-outpatient-switch-study-demonstrates-symptom-stability-during-transition-from-oral-atypical-antipsychotics-to-cobenfytm-xanomeline-and-trospium-chloride</guid>
<pubDate>Sat, 28 Mar 2026 11:00:00 GMT</pubDate>
<description>PRINCETON, N.J., March 28, 2026--Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy.</description>
</item>
<item>
<title>A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/a-new-era-in-schizophrenia-care-national-council-for-mental-wellbeing-and-bristol-myers-squibb-collaborate-to-advance-evidence-based-care-models</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/a-new-era-in-schizophrenia-care-national-council-for-mental-wellbeing-and-bristol-myers-squibb-collaborate-to-advance-evidence-based-care-models</guid>
<pubDate>Fri, 27 Mar 2026 11:29:00 GMT</pubDate>
<description>WASHINGTON, D.C. / ACCESS Newswire / March 27, 2026 /Originally published by the National Council for Mental Wellbeing The collaboration's first initiative is a white paper demonstrating the value of peer support programs to improve engagement, retention ...</description>
</item>
<item>
<title>insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/insitro-and-bristol-myers-squibb-collaboration-expanded-with-nomination-of-new-targets</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/insitro-and-bristol-myers-squibb-collaboration-expanded-with-nomination-of-new-targets</guid>
<pubDate>Mon, 23 Mar 2026 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 23, 2026--insitro, the AI therapeutics company built on causal biology, today announced the expansion of its strategic collaboration with Bristol Myers Squibb (NYSE: BMY) to advance a broadened portfolio of therapeutic programs for amyotrophic lateral sclerosis (ALS). The collaboration is focused on accelerating and delivering disease-modifying interventions designed to address the underlying biological drivers of ALS.</description>
</item>
<item>
<title>Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-reinforces-leadership-in-ohcm-with-new-camzyos-mavacamten-data-at-american-college-of-cardiology-annual-scientific-session-and-expo-2026-acc26</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-reinforces-leadership-in-ohcm-with-new-camzyos-mavacamten-data-at-american-college-of-cardiology-annual-scientific-session-and-expo-2026-acc26</guid>
<pubDate>Mon, 23 Mar 2026 10:59:00 GMT</pubDate>
<description>PRINCETON, N.J., March 23, 2026--BMS Reinforces Leadership in oHCM with New Camzyos Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)</description>
</item>
<item>
<title>Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-transforms-the-classical-hodgkin-lymphoma-treatment-paradigm-with-expanded-us-and-ema-approvals-for-opdivor-nivolumab</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-transforms-the-classical-hodgkin-lymphoma-treatment-paradigm-with-expanded-us-and-ema-approvals-for-opdivor-nivolumab</guid>
<pubDate>Fri, 20 Mar 2026 20:42:00 GMT</pubDate>
<description>PRINCETON, N.J., March 20, 2026--Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)</description>
</item>
<item>
<title>Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-to-report-results-for-first-quarter-2026-on-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-to-report-results-for-first-quarter-2026-on-april-30-2026</guid>
<pubDate>Thu, 19 Mar 2026 10:59:00 GMT</pubDate>
<description>PRINCETON, N.J., March 19, 2026--Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026</description>
</item>
<item>
<title>Colgate-Palmolive Announces Quarterly Dividend Increase and Elects Christopher Boerner, Ph.D. to Board of Directors</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/colgate-palmolive-announces-quarterly-dividend-increase-and-elects-christopher-boerner-phd-to-board-of-directors-61</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/colgate-palmolive-announces-quarterly-dividend-increase-and-elects-christopher-boerner-phd-to-board-of-directors-61</guid>
<pubDate>Thu, 12 Mar 2026 20:30:00 GMT</pubDate>
<description>NEW YORK, March 12, 2026--The Board of Directors of Colgate-Palmolive Company (NYSE:CL) today announced an increase in the quarterly common stock cash dividend to $0.53 up from $0.52 per share. The increase will be effective in the second quarter, 2026. The Board declared that the second quarter dividend is to be paid on May 15, 2026, to shareholders of record on April 20, 2026. On an annualized basis, the new dividend rate is $2.12 versus $2.08 per share previously. The Company has paid uninter</description>
</item>
<item>
<title>Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-announces-positive-phase-3-results-from-the-successor-2-study-of-oral-mezigdomide-in-relapsed-or-refractory-multiple-myeloma</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-announces-positive-phase-3-results-from-the-successor-2-study-of-oral-mezigdomide-in-relapsed-or-refractory-multiple-myeloma</guid>
<pubDate>Mon, 09 Mar 2026 10:59:00 GMT</pubDate>
<description>PRINCETON, N.J., March 09, 2026--Bristol Myers Squibb Announces Positive Phase 3 Data from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma</description>
</item>
<item>
<title>U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/us-fda-approves-bristol-myers-squibbs-sotyktur-deucravacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/us-fda-approves-bristol-myers-squibbs-sotyktur-deucravacitinib-for-the-treatment-of-adults-with-active-psoriatic-arthritis</guid>
<pubDate>Sat, 07 Mar 2026 02:59:00 GMT</pubDate>
<description>PRINCETON, N.J., March 07, 2026--U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis</description>
</item>
<item>
<title>Bristol Myers Squibb Announces Dividend</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-announces-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-announces-dividend</guid>
<pubDate>Mon, 02 Mar 2026 21:16:00 GMT</pubDate>
<description>PRINCETON, N.J., March 02, 2026--Bristol Myers Squibb Announces Dividend</description>
</item>
<item>
<title>SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/systimmune-and-bristol-myers-squibb-highlight-positive-phase-iii-interim-topline-results-for-izalontamab-brengitecan-iza-bren-in-previously-treated-unresectable-locally-advanced-or-metastatic-triple-negative-breast-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/systimmune-and-bristol-myers-squibb-highlight-positive-phase-iii-interim-topline-results-for-izalontamab-brengitecan-iza-bren-in-previously-treated-unresectable-locally-advanced-or-metastatic-triple-negative-breast-cancer</guid>
<pubDate>Thu, 26 Feb 2026 11:59:00 GMT</pubDate>
<description>REDMOND, Wash. & PRINCETON, N.J., February 26, 2026--SystImmune and BMS Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously-Treated Unresectable...</description>
</item>
<item>
<title>Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Mon, 23 Feb 2026 21:16:00 GMT</pubDate>
<description>PRINCETON, N.J., February 23, 2026--Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference</description>
</item>
<item>
<title>Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-announces-positive-top-line-results-from-registrational-phase-2-study-of-luspatercept-in-adults-with-alpha-a-thalassemia</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/bristol-myers-squibb-announces-positive-top-line-results-from-registrational-phase-2-study-of-luspatercept-in-adults-with-alpha-a-thalassemia</guid>
<pubDate>Mon, 23 Feb 2026 11:59:00 GMT</pubDate>
<description>PRINCETON, N.J., February 23, 2026--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia</description>
</item>
<item>
<title>Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights</title>
<link>https://6ix.com/company/bristol-myers-squibb-company/news/prothena-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financial-guidance-and-business-highlights-1</link>
<guid isPermaLink="true">https://6ix.com/company/bristol-myers-squibb-company/news/prothena-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-financial-guidance-and-business-highlights-1</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>DUBLIN, February 19, 2026--Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights</description>
</item>
</channel>
</rss>